Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Poulakidas, E."'
Autor:
Kotsianidis, I., Hatzimichael, E., Pappa, V., Galanopoulos, A., Kourakli, A., Diamantopoulos, P., Papageorgiou, S., Liapis, K., Papadopoulos, V., Papoutselis, M., Bouchla, A., Georgoulis, V., Vassilakopoulos, T., Solomou, E., Dimou, M., Vassilopoulos, G., Vardi, A., Papaioannou, M., Pontikoglou, C., Anagnostopoulos, A., Panayiotidis, P., Kontopidou, F., Harchalakis, N., Adamopoulos, N., Ximeri, M., Zikos, P., Megalakaki, A., Repousis, P., Kotsopoulou, M., Dryllis, G., Tsoukanas, D., Kyrtsonis, M.-C., Poulakidas, E., Bouronikou, E., Delimpasis, S., Mparmparousi, D., Papadaki, H., Vyniou, N.A., Symeonidis, A.
Publikováno v:
In Leukemia Research May 2023 128 Supplement
Background: 5-azacytidine (5-AZA) improves survival of patients with higher-risk myelodysplastic syndromes (MDSs) and oligoblastic acute myeloid leukemia (AML); however, predictive factors for response and outcome have not been consistently studied.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::2f1346cbba3a388fdd0c272409f84d91
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3104904
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3104904
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::69c4e1cdc6c7e2f9f8086fa1ea1455b3
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086446
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086446
In this study, we investigated the incidence and prognostic impact of monosomal karyotype (MK) in 405 higher-risk Myelodysplastic Syndromes (MDS) patients treated with 5-AZA. The MK was present in 66 out of 405 (16.3%) patients, most of whom had comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::8c977081807354576443849bb9bd354f
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107292
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107292
The demethylating factor 5-azacytidine (5-AZA) improves survival in intermediate-2 and high-risk myelodysplastic syndrome (MDS) patients [according to the International Prognostic Score System (IPSS)] responding to treatment. However, the outcome of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::224499392c34225e5bdf35d20b7ae8bd
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086564
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086564
Among various laboratory and clinical features megakaryocytopoiesis and platelet (PLT) counts have been previously insufficiently evaluated for their prognostic significance in acute myelogenous leukaemia (AML). We studied several clinical and labora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::e72f5faddcf3fce84116dd8e949e2726
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3095855
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3095855